{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:01:57Z","timestamp":1787500917678,"version":"build-2736575974"},"reference-count":11,"publisher":"BMJ","issue":"10","funder":[{"DOI":"10.13039\/100008894","name":"Stryker","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008894","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J NeuroIntervent Surg"],"accepted":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>One-year and 3-year outcomes for the SCENT trial have previously been reported. However, 5-year (long-term) clinical outcomes have not previously been described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter prospective trial, 180 aneurysms in 180 subjects were treated with the Surpass flow diverter system across 26 sites. Patients were followed according to a standardized protocol at 1\u2009month, 6 months, 1 year, 3 years, and 5 years. Aneurysm occlusion, in-stent stenosis, modified Rankin Scale (mRS) scores, and complications were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 5-year clinical follow-up reported 119 subjects and nine deaths with a completion rate of 71.1%, with 5-year angiographic follow-up available in 82 of the surviving 171 patients (48%). Aneurysm occlusion (Raymond Class I) for those patients who underwent angiographic follow-up was 77.8% (91\/117) and 90.2% (74\/82) at 3 and 5 years. The primary effectiveness composite endpoint was achieved in 80.3% (57\/71) of patients. The cumulative proportion of subjects experiencing new or worsening major ipsilateral stroke was 12.8% (23\/180) at 36 months, with no new occurrences at 60 months. No late aneurysm ruptures occurred during the 5-year follow-up, and no additional retreatments occurred between 36 and 60 months. Between 3 and 5 years, 52 potential site-reported serious adverse events were sent to CEC for adjudication. Of these, nine were CEC-adjudicated to be serious and four were determined to be related to the procedure\/device.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Five-year findings demonstrate the long-term safety and effectiveness of the Surpass flow diverter for intracranial aneurysm treatment, supported by high occlusion rates and low rates of delayed adverse events in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01716117\">NCT01716117<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnis-2024-022977","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T19:35:12Z","timestamp":1746646512000},"page":"1078-1082","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Five-year results of the SCENT trial with Surpass flow diverters to treat large or giant wide-neck aneurysms"],"prefix":"10.1136","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct01716117","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01716117","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3250-5543","authenticated-orcid":false,"given":"Philip M","family":"Meyers","sequence":"first","affiliation":[{"name":"Radiology and Neurological Surgery, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L","family":"Coon","sequence":"additional","affiliation":[{"name":"Carondelet Neurological Institute, Carondelet Saint Joseph\u2019s Hospital, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-4128","authenticated-orcid":false,"given":"Peter","family":"Kan","sequence":"additional","affiliation":[{"name":"Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aclan","family":"Dogan","sequence":"additional","affiliation":[{"name":"Interventional Neuroradiology, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bain","sequence":"additional","affiliation":[{"name":"Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu G","family":"Welch","sequence":"additional","affiliation":[{"name":"Neurosurgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ebersole","sequence":"additional","affiliation":[{"name":"Neurosurgery, Radiology, University of Kansas, Kansas City, Kansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"De Vries","sequence":"additional","affiliation":[{"name":"Neurosurgery, Radboud Universiteit, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4355-2107","authenticated-orcid":false,"given":"Ajay K","family":"Wakhloo","sequence":"additional","affiliation":[{"name":"Neurointerventional Radiology, Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Taussky","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Utah Hospital, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Stryker Neurovascular, Fremont, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A","family":"Hanel","sequence":"additional","affiliation":[{"name":"Cerebrovascular Surgery, Baptist Neurological Institute, Lyerly Neurosurgery, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2025091202150612000_17.10.1078.1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.678151"},{"key":"2025091202150612000_17.10.1078.2","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2020-015877"},{"key":"2025091202150612000_17.10.1078.3","doi-asserted-by":"publisher","DOI":"10.3171\/2015.6.JNS15311"},{"key":"2025091202150612000_17.10.1078.4","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2019-015696"},{"key":"2025091202150612000_17.10.1078.5","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.024135"},{"key":"2025091202150612000_17.10.1078.6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3171\/2019.8.JNS183078","article-title":"Giant intracranial aneurysms: natural history and 1-year case fatality after endovascular or surgical treatment","volume":"134","author":"Dengler","year":"2021","journal-title":"J Neurosurg"},{"key":"2025091202150612000_17.10.1078.7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00701-011-1022-5","article-title":"Mortality rates for giant aneurysms","volume":"153","author":"Hakma","year":"2011","journal-title":"Acta Neurochir (Wien)"},{"key":"2025091202150612000_17.10.1078.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13860-3"},{"key":"2025091202150612000_17.10.1078.9","article-title":"Managing thrombosis risk in flow diversion: A review of antiplatelet approaches","volume":"2025","author":"Toma","year":"2025","journal-title":"Neuroradiol J"},{"key":"2025091202150612000_17.10.1078.10","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyw014"},{"key":"2025091202150612000_17.10.1078.11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00062-023-01346-3","article-title":"Long-term Follow-up After Aneurysm Treatment with the Flow Redirection Endoluminal Device (FRED) Flow Diverter","volume":"34","author":"Hohenstatt","year":"2024","journal-title":"Clin Neuroradiol"}],"container-title":["Journal of NeuroInterventional Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnis-2024-022977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T13:01:15Z","timestamp":1759928475000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnis.bmj.com\/lookup\/doi\/10.1136\/jnis-2024-022977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jnis-2024-022977"],"URL":"https:\/\/doi.org\/10.1136\/jnis-2024-022977","relation":{},"ISSN":["1759-8478","1759-8486"],"issn-type":[{"value":"1759-8478","type":"print"},{"value":"1759-8486","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}